ClinicalTrials.gg

Program

ICP-332

A development code. Also written as “ICP-332 Tablets”.

Its studies are mostly in Dermatitis, Atopic · Psoriasis · Chronic Urticaria · Vitiligo, led by InnoCare Pharma.

Furthest: phase 3, since Dec 25, 20247 company-led studies, 4 open or runningNext primary completion: Nov 25, 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
InnoCare Pharma74 open or runningphase 3since Dec 25, 2024May 22, 2022Nov 25, 2026phase 3 · NCT06775860

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 22, 2022First study: phase 1 study in Healthy SubjectsFirst studyNCT05399030 · 72 enrolled · China
  2. Jan 10, 2023Phase 2 study in Moderate to Severe Atopic DermatitisNCT05702268 · 75 planned · China
  3. Jul 28, 2024Phase 1 study in Healthy SubjectsNCT06530966 · 24 enrolled · United States
  4. Dec 25, 2024Phase 3 study in Dermatitis, AtopicNCT06775860 · 552 planned · China
  5. Jun 23, 2025Phase 3 study in Non Segmental VitiligoNCT07047612 · 603 planned · China
  6. Nov 19, 2025Phase 2 study in Plaque PsoriasisNCT07251998 · 182 enrolled · China
  7. Jan 23, 2026Phase 3 study in Chronic UrticariaNCT07378527 · 344 planned · China

Ahead

  1. Nov 25, 2026Primary completion: phase 3 study in Dermatitis, AtopicNCT06775860
  2. Sep 2028Primary completion: phase 3 study in Chronic UrticariaNCT07378527
  3. Apr 2029Primary completion: phase 3 study in Non Segmental VitiligoNCT07047612

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 7 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07378527Chronic Urticaria · China3RecruitingSep 2028344
NCT07251998Plaque Psoriasis · China2CompletedOct 30, 2026182
NCT07047612Non Segmental Vitiligo · China3RecruitingApr 2029603
NCT06775860Dermatitis, Atopic · China3RecruitingNov 25, 2026552
NCT06530966Healthy Subjects · United States1CompletedNov 8, 202424
NCT05702268Moderate to Severe Atopic Dermatitis · China2RecruitingJul 30, 202375
NCT05399030Healthy Subjects · China1CompletedJan 30, 202272

How it is read

Names in the registry

  • “ICP-332 Tablets”, 8 entries
  • “ICP-332”, 2 entries

Codes read as this program: ICP332.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.